Wellington Management Group’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRV
Wellington Management Group's ACRV Position: Q3 2026 in Review
Wellington Management Group held its Acrivon Therapeutics (ACRV) position steady in Q3 2026 at 888,130 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.
Wellington Management Group first reported a position in ACRV in Q4 2022 and has held it in 16 quarters since. The position peaked at $11.5M in Q2 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.
- Wellington Management Group held 888,130 shares of Acrivon Therapeutics worth $1.82M as of Q3 2026.
- Wellington Management Group left its Acrivon Therapeutics share count unchanged in Q3 2026.
- Acrivon Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q3 2026, its #1615 holding.
- Wellington Management Group first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 16 quarters since.
- Wellington Management Group's Acrivon Therapeutics position peaked at $11.5M in Q2 2023.
- 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.
Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.